Goldman Sachs raises Lilly target to USD 1,413: Eli Lilly and Co. stock falls 1.53 percent
Published on 10/21/2026 at 11:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGoldman target and earnings date
- Goldman Sachs raised its Eli Lilly target from USD 1,371.00 to USD 1,413.00 on October 20, 2026.
- Second-quarter 2026 revenue reached USD 22.97 billion, up 47.7 percent year over year.
- Eli Lilly and Co. stock trades at EUR 1,137.30 at 11:04 a.m. CEST at Lang & Schwarz on October 21, 2026, 1.53 percent below the Xetra close of October 20, 2026.
Eli Lilly and Co. (ISIN US5324571083) was trading at EUR 1,137.30 at Lang & Schwarz on October 21, 2026, at 11:04 a.m. CEST, down 1.53 percent versus the Xetra close of October 20, 2026. Yahoo Finance reported on October 20 that Goldman Sachs raised its price target from USD 1,371.00 to USD 1,413.00 and kept its Buy rating.
Goldman raises the earnings bar
The target increase arrived before Lilly's third-quarter results, scheduled for October 29. The same report said the new target followed a USD 1,397.00 target from Bank of America, which had raised its target from USD 1,341.00.
The valuation case depends on continued growth in Lilly's diabetes and obesity portfolio. Goldman Sachs cited stronger-than-expected Mounjaro sales outside the United States and Zepbound volume gains linked to the Medicare GLP-1 Bridge program.
What does the growth require?
MarketBeat reported that second-quarter 2026 revenue rose 47.7 percent year over year to USD 22.97 billion, while earnings per share reached USD 8.38 versus USD 6.40 consensus. Lilly's fiscal 2026 adjusted earnings-per-share guidance stood at USD 35.50 to USD 36.50.
Three dates shape the setup
On October 9, 2026, Lilly published new Phase 3b data. On October 15, 2026, the company confirmed its third-quarter 2026 results date for October 29, 2026. On October 20, 2026, Goldman Sachs raised its target from USD 1,371.00 to USD 1,413.00, the latest of the three events.
When are the next milestones?
The next two company dates are October 29, 2026, for the third-quarter earnings call, and December 7, 2026, for Lilly Innovation Day. Both dates appear on the company's investor-relations page, which also lists the October 9 Phase 3b announcement and the October 15 results-date confirmation.
Stock price reflects a high hurdle
Lilly's current euro quote sits below the Xetra close even as the US-listed stock remains near its quoted 52-week high. The combination puts the October 29 results in direct focus: revenue growth must continue to justify elevated expectations, while the obesity and diabetes portfolio remains the main operating driver.
The stock was trading at EUR 1,137.30 at Lang & Schwarz on October 21, 2026, at 11:04 a.m. CEST, 1.53 percent below the Xetra close of October 20, 2026 at EUR 1,155.00. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly and Co stock.
Eli Lilly and Co. stock facts
- Company: Eli Lilly and Company
- ISIN: US5324571083
- Ticker: LLY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 21, 2026, 11:04 a.m. CEST): EUR 1,137.30
- Change versus Xetra close: minus 1.53 percent
- Xetra close (October 20, 2026): EUR 1,155.00
- Market capitalization: USD 1.2 trillion (as of October 21, 2026)
- 52-week range: USD 793.82-1,311.75 (as of October 21, 2026)
- Sector / Industry: Health care / Pharmaceuticals
Market context: Market report S&P 500.
